Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Filtrer les résultats de recherche
Sélectionner modèles de données

Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

2 Résultats de recherche.

Open-label Tarceva, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27/09/2016 - 1 Formulaire, 3 Groupes Item, 11 Eléments de données, 1 Langue

Groupes Item: Open Label Tarceva Consent, Eligibility, Investigator Signature

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Open-label Tarceva Consent and Eligibility

Withdrawal of Consent, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Withdrawal of Consent, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27/09/2016 - 1 Formulaire, 4 Groupes Item, 8 Eléments de données, 1 Langue

Groupes Item: Withdrawal of Treatment Consent, Withdrawal of Tissue Consent, Withdrawal of Optional Research Blood Sample Consent, Investigator Signature

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part: Withdrawal of Consent

Mots-clés

Table des matières

Modèles de données sélectionnés

Open-label Tarceva, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Withdrawal of Consent, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Withdrawal of Consent, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Mots-clés

Table des matières

Modèles de données sélectionnés

Open-label Tarceva, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Withdrawal of Consent, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Withdrawal of Consent, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

Contact

Aide